New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2013
11:43 EDTACT, NVS, BAYRYAppeals court reverses ruling in Actavis patent suit against Bayer
Watson Pharmaceuticals, now known as Actavis (ACT), along with Novartis' (NVS) Sandoz, unit and Lupin Pharmaceuticals, appealed the final judgments of the United States District Court for the District of Nevada in favor of Bayer Healthcare Pharmaceuticals and Bayer Schering Pharma (BAYRY). The Defendants challenged the district court’s entry of summary judgment that asserted claims 13 and 15 of Bayer’s U.S. "’564 patent” are not invalid for obviousness. The appeals court ruled in favor of the generic drug makers and reversed the lower court ruling. Reference Link
News For ACT;BAYRY;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 20, 2015
07:41 EDTNVS, BAYRY, ACTAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
15:55 EDTNVSAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTNVSAmgen denied preliminary injunction for biologics against Novartis, Reuters says
March 18, 2015
08:50 EDTACTActavis price target raised to $373 from $286 at BMO Capital
Subscribe for More Information
March 17, 2015
12:51 EDTNVSNovartis hit with $100M gender discrimination lawsuit, Reuters reports
A proposed class action lawsuit against Novartis claims the drug maker routinely denied female employees equal pay and promotional opportunities, reports Reuters. The $110M lawsuit filed on Tuesday says Novartis' Alcon Laboratories maintains a "boy's club atmosphere" that is hostile to women and bars them from leadership positions. Reference Link
09:19 EDTACTActavis reinstated with a Conviction Buy at Goldman
Subscribe for More Information
09:13 EDTACTActavis says Allergan CEO not joining combined company board
Subscribe for More Information
08:59 EDTACTActavis sees combined annual pro forma revenues of over $23B in 2015
Subscribe for More Information
08:58 EDTACTActavis sees double digit accretion to adjusted EPS within first 12 months
08:58 EDTACTActavis says will 'immediately begin implementing' integration plans
Subscribe for More Information
08:57 EDTACTActavis completes acquisition of Allergan
Actavis plc (ACT) announced that it has completed the acquisition of Allergan (AGN) in a cash and equity transaction valued at approximately $70.5B. The combination creates one of the world’s top 10 pharmaceutical companies by sales revenue, with combined annual pro forma revenues of more than $23B anticipated in 2015. Actavis continues to expect the transaction to generate double-digit accretion to non-GAAP earnings within the first 12 months, including approximately $1.8B in operating and financial synergies to be realized within one year following the close. These synergies exclude any additional revenue or manufacturing synergies, and are in addition to the $475M of annual savings previously announced by Allergan in connection with Project Endurance. Actavis further expects to generate strong operating cash flow in excess of $8B in 2016, which would enable the company to rapidly de-lever the balance sheet.
08:56 EDTACTActavis completes Allergan acquisition valued at $70.5B
Subscribe for More Information
05:32 EDTNVSIncyte announces Novartis receives EC approval for Jakavi
Incyte (INCY) announced that Novartis (NVS) received approval from the European Commission for Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Jakafi is approved by the FDA for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis, or MF, including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
05:30 EDTNVSNovartis receives EU approval for Jakavi in polycythemia vera
Novartis announced that the European Commission has approved Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Jakavi is the only JAK 1/2 inhibitor available to treat PV and is also currently approved in more than 80 countries to treat myelofibrosis.
March 16, 2015
18:38 EDTACTAmerican Airlines to replace Allergan in S&P 500 as of 3/20 close
Subscribe for More Information
16:10 EDTACTActavis receives FDA approval for VIIBRYD 20mg once daily
Subscribe for More Information
10:22 EDTACTEuropean Commission clears Actavis' pending acquisition of Allergan
Subscribe for More Information
March 13, 2015
17:33 EDTACTS&P announces changes to S&P 100 Index
Subscribe for More Information
08:03 EDTACTActavis receives FDA approval SAPHRIS for pediatric patients
Actavis announced that the FDA has approved its supplemental new drug application for SAPHRIS as monotherapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients. SAPHRIS is the only atypical antipsychotic treatment option with a sublingual formulation. The FDA approval of SAPHRIS is based on the results of a 3-week monotherapy trial in 403 pediatric patients, of which 302 pediatric patients received SAPHRIS twice daily in doses of either 2.5 mg, 5 mg or 10 mg. SAPHRIS was shown to demonstrate improvement in Young Mania Rating Scale total score and Clinical Global Impression-Bipolar Severity of Illness overall score versus placebo in a pediatric clinical trial.
05:40 EDTNVSNovartis to present Cosentyx data at AAD 2015
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use